---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-24-000197"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:55:59.194702+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q3 net loss $39.2M; ATEV BLA review ongoing with no new timeline

## Summary
- Net loss $39.2M (Q3 2024) vs $26.0M (Q3 2023) driven by non-cash contingent earnout remeasurement.
- Cash $71M at Sep 30; received $29.6M net from Oct registered direct offering.
- FDA BLA for ATEV in vascular trauma still under review; no new PDUFA date provided.
- V007 Phase 3 AV access data presented at ASN Kidney Week: ATEV superior patency vs fistula in key subgroups.
- Submitted NTAP reimbursement application to CMS for FY2026 cycle (Oct 2025 effective date if approved).

## SEC filing metadata
- accession: 0001818382-24-000197
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000197/0001818382-24-000197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000197/huma-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-24-000197
- JSON: https://secwatch.observer/filing/0001818382-24-000197.json
- Plain text: https://secwatch.observer/filing/0001818382-24-000197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.